Purchase this article with an account.
Srinivas R. Sadda; Imaging biomarkers for AMD and retinal dystrophies for testing new drugs. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2583.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
Retinal imaging technologies have undergone a rapid evolution over the past two decades. The broad clinical availabaility of multimodal imaging technique has created opportunities for the development of new biomarkers which can be used to more precisely diagnose, risk stratify, stage, and monitor the progression of AMD and various retinal dystrophies. For example, various OCT features including drusen volume, subretinal drusenoid deposits, hyporeflective drusen, and intraretinal hyper-reflective features have been idenfitifed as risk factors for development of advanced AMD. Non-exudative neovascular lesions identified by OCT angiography have been shown to predict the development of future exudative complications. Alterations in the choricapillaris on OCT-A have been identified in early and intermediate AMD eyes. These characteristics may be usfeul for selecting the optimal patients for enrollment in future trials. In addition, OCT-based criteria for the recognition of macular atrophy have been defined, which may allow for more precise monitoring of disease progression and assessment of therapeutic response. Moreover, criteria for earlier or incomplete stages of atrophy have been defined which may facilitate the development of early intervention trials. Finally, for inherited retinal diseases the concepts of ellipsoid zone (EZ) width/area and EZ defect area have been introduced, and may prove to be reliable outcome measures for therapeutic trials.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only